Premium
Down‐regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer
Author(s) -
Wang Shuang,
Zhou Jun,
Wang XiaoYan,
Hao JunMei,
Chen JuanZhi,
Zhang XiangMei,
Jin He,
Liu Li,
Zhang YanFei,
Liu Jinsong,
Ding YanQing,
Li JianMing
Publication year - 2009
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.2575
Subject(s) - colorectal cancer , metastasis , cancer research , medicine , gene expression profiling , immunohistochemistry , oncology , in vivo , gene expression , cancer , pathology , gene , biology , biochemistry , microbiology and biotechnology
To identify novel biomarkers of metastasis of colorectal cancer (CRC), we developed an orthotopic implantation model of murine CRC and selected in vivo M5, a subclone of the SW480 CRC cell line with enhanced potential for metastasis to the liver. We compared the differences in the gene expression profiles between M5 and SW480 cells using gene expression profiling. We found that expression of special AT‐rich sequence‐binding protein 2 (SATB2) was down‐regulated in M5 cells. Immunohistochemical analysis of 146 colorectal tumour samples showed that underexpression of SATB2 was strongly correlated with poor prognosis, tumour invasion, lymph node metastasis, distant metastasis, and Dukes' classification for CRC. Univariate and multivariate survival analyses further showed that SATB2 expression was a potential favourable prognostic factor for CRC. These results demonstrated not only that SATB2 is a potential novel prognostic factor for CRC, but also that selection of a highly metastatic clone of SW480 in vivo coupled with gene expression profiling is a powerful approach to identifying prognostic markers for CRC. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.